Acute Myeloid Leukemia Market worth $17.1 billion by 2024

-

According to the new market research report the acute myeloid leukemia market is projected to reach USD 17.1 billion by 2024 from USD 12.3 billion in 2019, at a CAGR of 6.8% during the forecast period.

Ask For PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223

Growth in this market is largely driven by the growing geriatric population and the introduction of innovative therapies for the treatment of leukemia. However, complexities in manufacturing serve as a key restraint to market growth.

The major players in the acute myeloid leukemia market are Sanofi (France), AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland), F. Hoffmann-La Roche (Switzerland), Pfizer (US), Amgen (US), Takeda Pharmaceutical (Japan), Gilead Sciences (US), and Celgene (US). Product launches and acquisitions are the key growth strategies adopted by most players in this market.

Based on treatment type, the acute myeloid leukemia market is bifurcated into chemotherapy and targeted drugs & immunotherapy. Of these, the targeted drugs & immunotherapy segment accounted for the largest market share in 2018. Factors such as the increasing demand for targeted drugs, development of novel immunotherapies for the treatment of leukemia, and higher efficacy and success rate associated with targeted drugs & immunotherapy as compared to chemotherapy are driving the growth of this segment.

Based on the type of leukemia, the leukemia therapeutics market is segmented into acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). Of these, the chronic myeloid leukemia segment accounted for the largest market share in 2018. It is also anticipated to register the highest growth during the forecast period. This market is primarily driven by certain factors such as high incidences of chronic myeloid leukemia and the wide range of treatment options available for its treatment.

The North American acute myeloid leukemia market is expected to account for the largest share, globally. The rising number of leukemia patients, tissue engineering, new drugs & therapies launches, and high research funding for the treatment of leukemia are the major driving factors in this market. In 2018, according to the Leukemia & Lymphoma Society, an estimated 381,774 people were living with or in remission from leukemia in the US. According to the Canadian Cancer Society, nearly 138,100 people in Canada are living with or are in remission from blood cancer (data as of 2016). In addition, nearly 22,340 Canadians of all ages were diagnosed with a form of blood cancer, including 5,900 cases of leukemia.

Request Free Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=223

Comments

Post a Comment

Popular posts from this blog

Future of Remote Patient Monitoring Industry: Impact of Remote Patient Monitoring on Healthcare

-
Remote patient monitoring is a type of telemedicine technology that enables healthcare providers to monitor their patients’ health remotely. This technology utilizes remote devices that are placed in the patient’s home or worn by the patient to collect medical data such as vital signs and other medical information.  This medical data is then transmitted to the doctor or healthcare provider to help them make better decisions regarding the patient’s care. RPM can be used to monitor a variety of conditions including chronic diseases, mental health issues, and post-operative care. It can also be used to support elderly individuals and those with disabilities. RPM has the potential to improve patient outcomes and reduce healthcare costs by enabling healthcare providers to monitor their patients’ health more effectively. Benefits of Remote Patient Monitoring 1. Increased Patient Engagement: Remote patient monitoring systems provide patients with a convenient way to stay engaged in thei...
Read more

Strategies Adopted by the Major Players in this Digital PCR Market

-
 According to research report the  Digital PCR Market  is expected to grow from USD 3.47 billion in 2017 to USD 5.31 billion by 2022, at a CAGR of 8.9% during the forecast period. Product Launches: Key Strategy Adopted by the Major Players in this Market New product launches and approvals are the key growth strategies adopted by major players to strengthen their position in the global Digital PCR Market. Moreover, strategies such as partnerships, collaborations, and agreements; as well as mergers and acquisitions were also adopted by several market players to strengthen their market position, expand their R&D capabilities, and geographic presence in the global Digital PCR Market. The key players in the Digital PCR Market include Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluid...
Read more

Sinus Dilation Devices Market Size And Share Report, 2027

-
The sinus dilation devices market is on track for significant growth in the coming years, projected to reach USD 3.8 billion by 2027, up from USD 2.8 billion in 2022. This represents a compound annual growth rate (CAGR) of 6.6% during the forecast period. The market's expansion is largely driven by the increasing availability of reimbursements and rising cases of chronic sinusitis. However, the market faces challenges due to the availability of non-surgical treatments for chronic sinusitis and a shortage of skilled ENT surgeons. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64349810 Key Market Drivers Increasing Availability of Reimbursements: The growing availability of reimbursements for sinus dilation procedures is making them more accessible to patients, thereby driving demand for sinus dilation devices. Rising Incidence of Chronic Sinusitis: The prevalence of chronic sinusitis is on the rise globally, leading to an increase in d...
Read more